Biomarkers in Rheumatoid Arthritis: From Traditional Serology to Precision Medicine Integration
Diagnostics · 20.01.2026 · 16 (2) · 330
DOI: 10.3390/diagnostics16020330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 20.01.2026. Verfasst von Muhammad Soyfoo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hôpital Universitaire de Bruxelles, Université libre de Bruxelles, 1070 Brussels, Belgium. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The biomarker landscape in rheumatoid arthritis (RA) is evolving from reliance on traditional markers toward integrated, multimodal strategies enabling precision medicine approaches. To critically evaluate emerging biomarkers across serological, cellular, genetic, imaging, and multi-omic domains, distinguishing those approaching clinical readiness from those requiring further development. In this study, a narrative review of the literature published between 2000 and 2024 relevant to clinical decision-making in RA was conducted. Among novel serological markers, 14-3-3η protein and anti-carbamylated protein antibodies show the strongest validation for seronegative disease and prognostic stratification. Calprotectin demonstrates utility for disease activity monitoring and de-escalation decisions. Multi-biomarker disease activity scores provide an objective assessment but lack outcome trial validation. Musculoskeletal ultrasound offers accessible imaging biomarker capability, while MRI bone marrow edema remains the strongest structural progression predictor. Synovial tissue pathotyping has demonstrated proof-of-concept for treatment stratification. Genetic, epigenetic, and metabolomic approaches remain investigational. Key clinical implications include using 14-3-3η and calprotectin to inform seronegative diagnosis and de-escalation decisions, integrating ultrasound for remission verification, and recognizing that emerging biomarkers for extra-articular complications, including cardiovascular risk and venous thromboembolism, represent important unmet needs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Hôpital Universitaire de Bruxelles, Université libre de Bruxelles, 1070 Brussels, Belgium.
ORCID-Profile: Muhammad Soyfoo, Julie Sarrand
Zitieren
APA
Soyfoo, M., & Sarrand, J. (2026). Biomarkers in Rheumatoid Arthritis: From Traditional Serology to Precision Medicine Integration. Diagnostics, 16(2), 330. https://doi.org/10.3390/diagnostics16020330
Vancouver
Soyfoo M, Sarrand J. Biomarkers in Rheumatoid Arthritis: From Traditional Serology to Precision Medicine Integration. Diagnostics. 2026;16(2):330. doi:10.3390/diagnostics16020330
BibTeX
@article{Soyfoo2026,
author = {Soyfoo, Muhammad and Sarrand, Julie},
title = {Biomarkers in Rheumatoid Arthritis: From Traditional Serology to Precision Medicine Integration},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {2},
pages = {330},
doi = {10.3390/diagnostics16020330}
}
EUVIMED